

### Claims Amendments

Please **cancel** claims 31-32 and 43-51, **amend** claims 33-37 and 40-42, and **add** new claims 52-63, as indicated below. This listing of the claims will replace all other listings.

Claims 1-30. (Previously Cancelled)

Claims 31-32. (Currently Cancelled)

33. (Currently amended) A method of reducing gastric motility in a subject in need thereof comprising administering to said subject an amount of an exendin ~~or an exendin-agonist~~ effective for reducing gastric motility.

34. (Currently amended) A method of delaying gastric emptying in a subject in need thereof comprising administering to said subject an amount of an exendin ~~or an exendin-agonist~~ effective for delaying gastric emptying.

35. (Currently amended) The method according to claim ~~31, 32,~~ 33 or 34 wherein said exendin is ~~exendin-3~~ exendin-3.

36. (Currently amended) The method according to claim ~~31, 32,~~ 33 or 34 wherein said exendin is exendin-4.

37. (Currently amended) The method according to claim ~~31, 32,~~ 33 or 34 wherein said subject is undergoing a gastrointestinal diagnostic procedure.

38. (Previously presented) The method according to claim 37 wherein said gastrointestinal diagnostic procedure is a radiological examination.

39. (Previously presented) The method according to claim 38 wherein said gastric gastrointestinal diagnostic procedure is magnetic resonance imaging.

40. (Currently amended) The method according to claim ~~31 or 33 or 34~~ wherein said ~~gastric motility is associated with~~ subject is suffering from a gastrointestinal disorder.

41. (Currently amended) ~~The method according to claim 31, 32, 33 or 34 wherein said exendin-agonist~~ A method of reducing gastric motility in a subject in need thereof comprising administering to said subject an amount of an exendin analog

effective for reducing gastric motility, wherein said exendin analog is selected from a peptide compound of the formula [SEQ. ID. NO. 38]:

1	5	10
Xaa <sub>1</sub>	Xaa <sub>2</sub> Xaa <sub>3</sub>	Gly Thr Xaa <sub>4</sub> Xaa <sub>5</sub> , Xaa <sub>6</sub> Xaa <sub>7</sub> Xaa <sub>8</sub>
	15	20
Ser Lys Gln Xaa <sub>9</sub>	Glu Glu Glu Ala Val Arg Leu	
	25	30
Xaa <sub>10</sub> Xaa <sub>11</sub> Xaa <sub>12</sub> Xaa <sub>13</sub>	Leu Lys Asn Gly Gly Xaa <sub>14</sub>	
	35	
Ser Ser Gly Ala Xaa <sub>15</sub> Xaa <sub>16</sub> Xaa <sub>17</sub> Xaa <sub>18</sub>	-Z	

wherein:

Xaa<sub>1</sub> is His, Arg or Tyr;

Xaa<sub>2</sub> is Ser, Gly, Ala or Thr;

Xaa<sub>3</sub> is Asp or Glu;

Xaa<sub>4</sub> is Phe, Tyr or naphthylalanine;

Xaa<sub>5</sub> is Thr or Ser;

Xaa<sub>6</sub> is Ser or Thr;

Xaa<sub>7</sub> is Asp or Glu;

Xaa<sub>8</sub> is Leu, Ile, Val, pentylglycine or Met;

Xaa<sub>9</sub> is Leu, Ile, pentylglycine, Val or Met;

Xaa<sub>10</sub> is Phe, Tyr or naphthylalanine;

Xaa<sub>11</sub> is Ile, Val, Leu, pentylglycine, tert-butylglycine or Met;

Xaa<sub>12</sub> is Glu or Asp;

Xaa<sub>13</sub> is Trp, Phe, Tyr, or naphthylalanine;

Xaa<sub>14</sub>, Xaa<sub>15</sub>, Xaa<sub>16</sub> and Xaa<sub>17</sub> are independently Pro, homoproline, 3Hyp, 4Hyp, thioproline, N-alkylglycine, N-alkylpentylglycine or N-alkylalanine;

Xaa<sub>18</sub> is Ser, Thr or Tyr; and

Z is -OH or -NH<sub>2</sub>;

with the proviso that the compound does not have the formula of either exendin-3 [SEQ. ID. NO. 1] or exendin-4 [SEQ. ID. NO. 2] and pharmaceutically acceptable salts thereof.

42. (Currently amended) ~~The method according to claim 31, 32, 33 or 34 wherein said exendin agonist~~ A method of reducing gastric motility in a subject in need thereof comprising administering to said subject an amount of an exendin analog effective for reducing gastric motility, wherein said exendin analog is selected from a peptide compound of the formula [SEQ. ID. NO. 39]:

1	5	10
Xaa <sub>1</sub>	Xaa <sub>2</sub> Xaa <sub>3</sub>	Gly Thr Xaa <sub>4</sub> Xaa <sub>5</sub> , Xaa <sub>6</sub> Xaa <sub>7</sub> Xaa <sub>8</sub>
15	20	
Ser Lys Gln Xaa <sub>9</sub>	Glu Glu Glu Ala Val Arg Leu	
25	30	
Xaa <sub>10</sub> Xaa <sub>11</sub> Xaa <sub>12</sub>	Xaa <sub>13</sub> Leu Lys Asn Gly Gly Xaa <sub>14</sub>	
35		
Ser Ser Gly Ala Xaa <sub>15</sub>	Xaa <sub>16</sub> Xaa <sub>17</sub> Xaa <sub>18</sub>	-Z

wherein:

Xaa<sub>1</sub> is His or Arg;

Xaa<sub>2</sub> is Ser or Gly;

Xaa<sub>3</sub> is Asp or Glu;

Xaa<sub>4</sub> is Phe or naphthylalanine;

Xaa<sub>5</sub> is Thr or Ser;

Xaa<sub>6</sub> is Ser or Thr;

Xaa<sub>7</sub> is Asp or Glu;

Xaa<sub>8</sub> is Leu or pentylglycine

Xaa<sub>9</sub> is Leu or pentylglycine;

Xaa<sub>10</sub> is Phe or naphthylalanine;

Xaa<sub>11</sub> is Ile, Val or tert-butylglycine;

Xaa<sub>12</sub> is Glu or Asp;

Xaa<sub>13</sub> is Trp or Phe;

Xaa<sub>14</sub>, Xaa<sub>15</sub>, Xaa<sub>16</sub> and Xaa<sub>17</sub> are independently selected from Pro, homoproline or N-methylalanine;

Xaa<sub>18</sub> is Ser or Tyr; and

Z is -OH or -NH<sub>2</sub>;

with the proviso that the compound does not have the formula of either exendin-3 [SEQ. ID. NO. 1] or exendin-4 [SEQ. ID. NO. 2] and pharmaceutically acceptable salts thereof.

Claims 43-51. (Currently Cancelled)

52. (New) A method of delaying gastric emptying in a subject in need thereof comprising administering to said subject an amount of an exendin analog effective for delaying gastric emptying, wherein said exendin analog is selected from a peptide compound of the formula [SEQ. ID. NO. 38]:

1	5	10
Xaa <sub>1</sub>	Xaa <sub>2</sub> Xaa <sub>3</sub> Gly Thr Xaa <sub>4</sub> Xaa <sub>5</sub> , Xaa <sub>6</sub> Xaa <sub>7</sub> Xaa <sub>8</sub>	
	15	20
Ser Lys Gln Xaa <sub>9</sub> Glu Glu Glu Ala Val Arg Leu		
	25	30
Xaa <sub>10</sub> Xaa <sub>11</sub> Xaa <sub>12</sub> Xaa <sub>13</sub> Leu Lys Asn Gly Gly Xaa <sub>14</sub>		
	35	
Ser Ser Gly Ala Xaa <sub>15</sub> Xaa <sub>16</sub> Xaa <sub>17</sub> Xaa <sub>18</sub> -Z		

wherein:

Xaa<sub>1</sub> is His, Arg or Tyr;

Xaa<sub>2</sub> is Ser, Gly, Ala or Thr;

Xaa<sub>3</sub> is Asp or Glu;

Xaa<sub>4</sub> is Phe, Tyr or naphthylalanine;

Xaa<sub>5</sub> is Thr or Ser;

Xaa<sub>6</sub> is Ser or Thr;

Xaa<sub>7</sub> is Asp or Glu;

Xaa<sub>8</sub> is Leu, Ile, Val, pentylglycine or Met;

Xaa<sub>9</sub> is Leu, Ile, pentylglycine, Val or Met;

Xaa<sub>10</sub> is Phe, Tyr or naphthylalanine;

Xaa<sub>11</sub> is Ile, Val, Leu, pentylglycine, tert-butylglycine or Met;

Xaa<sub>12</sub> is Glu or Asp;

Xaa<sub>13</sub> is Trp, Phe, Tyr, or naphthylalanine;

Xaa<sub>14</sub>, Xaa<sub>15</sub>, Xaa<sub>16</sub> and Xaa<sub>17</sub> are independently Pro, homoproline, 3Hyp, 4Hyp, thioproline, N-alkylglycine, N-alkylpentylglycine or N-alkylalanine;

Xaa<sub>18</sub> is Ser, Thr or Tyr; and

Z is -OH or -NH<sub>2</sub>;

with the proviso that the compound does not have the formula of either exendin-3 [SEQ. ID. NO. 1] or exendin-4 [SEQ. ID. NO. 2] and pharmaceutically acceptable salts thereof.

53. (New) A method of delaying gastric emptying in a subject in need thereof comprising administering to said subject an amount of an exendin analog effective for delaying gastric emptying, wherein said exendin analog is selected from a peptide compound of the formula [SEQ. ID. NO. 39]:

1	5	10
Xaa <sub>1</sub>	Xaa <sub>2</sub> Xaa <sub>3</sub>	Gly Thr Xaa <sub>4</sub> Xaa <sub>5</sub> , Xaa <sub>6</sub> Xaa <sub>7</sub> Xaa <sub>8</sub>
	15	20
Ser Lys Gln Xaa <sub>9</sub>	Glu Glu Glu Ala Val Arg Leu	
	25	30
Xaa <sub>10</sub> Xaa <sub>11</sub> Xaa <sub>12</sub>	Xaa <sub>13</sub> Leu Lys Asn Gly Gly Xaa <sub>14</sub>	
	35	
Ser Ser Gly Ala Xaa <sub>15</sub>	Xaa <sub>16</sub> Xaa <sub>17</sub> Xaa <sub>18</sub> -Z	

wherein:

Xaa<sub>1</sub> is His or Arg;

Xaa<sub>2</sub> is Ser or Gly;

Xaa<sub>3</sub> is Asp or Glu;

Xaa<sub>4</sub> is Phe or naphthylalanine;

Xaa<sub>5</sub> is Thr or Ser;

Xaa<sub>6</sub> is Ser or Thr;

Xaa<sub>7</sub> is Asp or Glu;

Xaa<sub>8</sub> is Leu or pentylglycine

Xaa<sub>9</sub> is Leu or pentylglycine;

Xaa<sub>10</sub> is Phe or naphthylalanine;

Xaa<sub>11</sub> is Ile, Val or tert-butylglycine;

Xaa<sub>12</sub> is Glu or Asp;

Xaa<sub>13</sub> is Trp or Phe;

Xaa<sub>14</sub>, Xaa<sub>15</sub>, Xaa<sub>16</sub> and Xaa<sub>17</sub> are independently selected from Pro, homoproline

or N-methylalanine;

Xaa<sub>18</sub> is Ser or Tyr; and

Z is -OH or -NH<sub>2</sub>;

with the proviso that the compound does not have the formula of either exendin-3 [SEQ. ID. NO. 1] or exendin-4 [SEQ. ID. NO. 2] and pharmaceutically acceptable salts thereof.

54. (New) The method according to claim 41, 42, 52, or 53 wherein said subject is undergoing a gastrointestinal diagnostic procedure.

55. (New) The method according to claim 54 wherein said gastrointestinal diagnostic procedure is a radiological examination.

56. (New) The method according to claim 55 wherein said gastric gastrointestinal diagnostic procedure is magnetic resonance imaging.

57. (New) The method according to claim 41, 42, 52, or 53 wherein said subject is suffering from a gastrointestinal disorder.

58. (New) A method of reducing gastric motility in a subject in need thereof comprising administering to said subject an amount of exendin-4 effective for reducing gastric motility.

59. (New) A method of delaying gastric emptying in a subject in need thereof comprising administering to said subject an amount of exendin-4 effective for delaying gastric emptying.

60. (New) The method according to claim 58 or 59 wherein said subject is undergoing a gastrointestinal diagnostic procedure.

61. (New) The method according to claim 60 wherein said gastrointestinal diagnostic procedure is a radiological examination.

62. (New) The method according to claim 61 wherein said gastric gastrointestinal diagnostic procedure is magnetic resonance imaging.

63. (New) The method according to claim 58 or 59 wherein said subject is suffering from a gastrointestinal disorder.